Literature DB >> 29234627

Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®.

Veronica Salvatore1, Alice Gianstefani1, Giulia Negrini1, Giulia Allegretti1, Marzia Galassi1, Fabio Piscaglia1.   

Abstract

Due to the ability to detect the typical contrast-imaging pattern for hepatocellular carcinoma (HCC), that is hyperenhancement in the arterial phase and hypoenhancement in the late phase on a cirrhotic background, contrast-enhanced ultrasonography (CEUS) was included in the American diagnostic algorithm for HCC in 2005. However, its role has been questioned because of the possibility of misdiagnosis of cholangiocarcinoma. The present review aims to describe the advantages and disadvantages of CEUS applications using Sonovue® for HCC. In particular there is focus on the accuracy of CEUS in detecting the typical HCC pattern, the CEUS patterns of intrahepatic cholangiocarcinoma (ICC), the risk of misdiagnosis with HCC, the diagnostic use of CEUS in cases of locoregional and systemic treatments, and the evaluation of response to antiangiogenic treatment using dedicated software.

Entities:  

Keywords:  Cholangiocarcinoma; Cirrhosis; Diagnosis; Hepatocellular carcinoma; Treatment

Year:  2015        PMID: 29234627      PMCID: PMC5704684          DOI: 10.1159/000367748

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  68 in total

1.  Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008.

Authors:  M Claudon; D Cosgrove; T Albrecht; L Bolondi; M Bosio; F Calliada; J-M Correas; K Darge; C Dietrich; M D'Onofrio; D H Evans; C Filice; L Greiner; K Jäger; N de Jong; E Leen; R Lencioni; D Lindsell; A Martegani; S Meairs; C Nolsøe; F Piscaglia; P Ricci; G Seidel; B Skjoldbye; L Solbiati; L Thorelius; F Tranquart; H P Weskott; T Whittingham
Journal:  Ultraschall Med       Date:  2008-02       Impact factor: 6.548

2.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

3.  Percutaneous sonographically guided radio frequency ablation of hepatocellular carcinoma: causes of mistargeting and factors affecting the feasibility of a second ablation session.

Authors:  Min Woo Lee; Hyo K Lim; Young Jun Kim; Dongil Choi; Young-Sun Kim; Won Jae Lee; Dong Ik Cha; Min Jung Park; Hyunchul Rhim
Journal:  J Ultrasound Med       Date:  2011-05       Impact factor: 2.153

4.  Factors Affecting the Enhancement Patterns of Intrahepatic Cholangiocarcinoma (ICC) on Contrast-Enhanced Ultrasound (CEUS) and their Pathological Correlations in Patients with a Single Lesion.

Authors:  M X Yuan; R Li; X H Zhang; C L Tang; Y L Guo; D Y Guo; M K Luo
Journal:  Ultraschall Med       Date:  2015-04-28       Impact factor: 6.548

5.  Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?

Authors:  F Knieling; M J Waldner; R S Goertz; S Zopf; D Wildner; M F Neurath; T Bernatik; D Strobel
Journal:  Ultraschall Med       Date:  2012-12-20       Impact factor: 6.548

6.  Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.

Authors:  Marco Baron Toaldo; Veronica Salvatore; Sara Marinelli; Chiara Palamà; Maddalena Milazzo; Luca Croci; Laura Venerandi; Mario Cipone; Luigi Bolondi; Fabio Piscaglia
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

7.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.

Authors:  Maria Assunta Zocco; Matteo Garcovich; Andrea Lupascu; Enrico Di Stasio; Davide Roccarina; Brigida Elenora Annicchiarico; Laura Riccardi; Maria Elena Ainora; Francesca Ponziani; Gianluigi Caracciolo; Gian Lodovico Rapaccini; Raffaele Landolfi; Massimo Siciliano; Maurizio Pompili; Antonio Gasbarrini
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.

Authors:  Sara Marinelli; Veronica Salvatore; Marco Baron Toaldo; Maddalena Milazzo; Luca Croci; Laura Venerandi; Anna Pecorelli; Chiara Palamà; Alessia Diana; Luigi Bolondi; Fabio Piscaglia
Journal:  BMC Cancer       Date:  2014-06-04       Impact factor: 4.430

View more
  5 in total

1.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

2.  Distinguishing Hepatocellular Carcinoma From Hepatic Inflammatory Pseudotumor Using a Nomogram Based on Contrast-Enhanced Ultrasound.

Authors:  Mengting Liao; Chenshan Wang; Bo Zhang; Qin Jiang; Juan Liu; Jintang Liao
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

3.  Establishment of a Novel Mouse Hepatocellular Carcinoma Model for Dynamic Monitoring of Tumor Development by Bioluminescence Imaging.

Authors:  Xiangyi Cao; Yulong Zhang; Qianqian Zhou; Sujing Sun; Minwei He; Xiaohui Wang; Ping Ma; Xiaoang Yang; Liping Lv; Linsheng Zhan
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

Review 4.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

5.  Role of Contrast-Enhanced Ultrasonography in Hepatocellular Carcinoma by Using LI-RADS and Ancillary Features: A Single Tertiary Centre Experience.

Authors:  Adriana Ciocalteu; Sevastita Iordache; Sergiu Marian Cazacu; Cristiana Marinela Urhut; Sarmis Marian Sandulescu; Ana-Maria Ciurea; Adrian Saftoiu; Larisa Daniela Sandulescu
Journal:  Diagnostics (Basel)       Date:  2021-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.